LBPH
NASDAQLongboard Pharmaceuticals Inc.
News · 26 weeks10%
2025-12-072026-05-31
Mix190d
- Leadership1(100%)
Latest news
25 items- PRSensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual ReportGJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month efficacy data expected in Q1 2026 Strengthened balance sheet and shareholder registry via €60m financing in January 2026, including a €20m strategic investment from Sanofi; cash runway extended to end of H1 2027 Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2025 results, provided a corp
- PRSensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent DirectorRegulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b
- SECSEC Form 15-12G filed by Longboard Pharmaceuticals Inc.15-12G - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form POSASR filed by Longboard Pharmaceuticals Inc.POSASR - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form RW WD filed by Longboard Pharmaceuticals Inc.RW WD - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form EFFECT filed by Longboard Pharmaceuticals Inc.EFFECT - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form EFFECT filed by Longboard Pharmaceuticals Inc.EFFECT - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form EFFECT filed by Longboard Pharmaceuticals Inc.EFFECT - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- INSIDERSEC Form 4 filed by Director Lynch Casey4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
- INSIDERSEC Form 4 filed by Director Le Goff Corinne4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
- INSIDERSEC Form 4 filed by Director Sekhri Paul J4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
- INSIDERSEC Form 4 filed by Director Schneider Phillip M4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
- INSIDERSEC Form 4 filed by Director Aurentz Vincent4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
- INSIDERExecutive Vice President & CMO Kaye Randall closing all direct ownership in the company (SEC Form 4)4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
- INSIDERSEC Form 4 filed by Executive VP and CFO Roberts Brandi4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
- INSIDERPresident and CEO Lind Kevin Robert closing all direct ownership in the company (SEC Form 4)4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
- SECSEC Form RW filed by Longboard Pharmaceuticals Inc.RW - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form POS AM filed by Longboard Pharmaceuticals Inc.POS AM - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form POS AM filed by Longboard Pharmaceuticals Inc.POS AM - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECSEC Form POS AM filed by Longboard Pharmaceuticals Inc.POS AM - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
- SECLongboard Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits8-K - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
LBPH FAQ
7 questionsWhat does Longboard Pharmaceuticals Inc. do?
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The...Where does LBPH stock trade?
Longboard Pharmaceuticals Inc. (LBPH) is listed on NASDAQ.What sector and industry is LBPH in?
Longboard Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Longboard Pharmaceuticals Inc. go public?
Longboard Pharmaceuticals Inc. (LBPH) completed its IPO in 2021.What are analysts saying about LBPH?
Longboard Pharmaceuticals Inc. has had 7 recent analyst actions on file. The most recent action was from Truist: Buy on 2024-09-10. Recent price targets range from $1300.00 to $4000.00.What companies are similar to LBPH?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LBPH side-by-side with any of them on Quantisnow.How can I track LBPH on Quantisnow?
Quantisnow aggregates Longboard Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LBPH to receive live email and push alerts on every new disclosure.